Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves

6 hours ago 2

MarketBeat

Tue, June 16, 2026 astatine 11:06 AM CDT 7 min read

Key Points

Interested successful Agenus Inc.? Here are 5 stocks we similar better.
BOT/BAL remains Agenus' main focus arsenic the institution advances botensilimab/balstilimab successful hard-to-treat cancers, particularly refractory MSS metastatic colorectal cancer. Management said the programme has treated astir 1,300 patients and is present the pb campaigner for signifier 3 and regulatory development.
The planetary phase 3 BATMAN trial is underway, comparing BOT/BAL with champion supportive attraction successful refractory MSS oregon pMMR metastatic colorectal cancer. Agenus expects the archetypal wide endurance readout successful the second fractional of 2028.
Agenus said its balance expanse has improved aft the Zydus collaboration, rising from astir $3 cardinal successful currency astatine the extremity of 2025 to astir $35 cardinal successful currency astatine the extremity of Q1 2026, positive further ATM proceeds afterward. The institution is besides preparing imaginable accelerated support filings successful the U.S. and conditional selling authorization plans successful Europe.

Agenus (NASDAQ:AGEN) told shareholders astatine its 2026 virtual yearly gathering that it remains focused connected advancing its botensilimab and balstilimab immunotherapy combination, known arsenic BOT/BAL, portion moving to fortify its fiscal presumption and prosecute regulatory pathways successful the United States and Europe.

Chairman and Chief Executive Officer Garo Armen said the past twelvemonth had been "one of the astir important periods" successful the company's history, but besides "one of the astir difficult." He said Agenus had made "hard decisions" to sharpen its absorption astir BOT/BAL, which the institution is processing successful cancers that person historically resisted immunotherapy, including microsatellite stable, oregon MSS, colorectal cancer.

→ Viasat's Orbiting Profits: Space Force Jackpot?

Armen said the company's cardinal objectives see gathering objective grounds for BOT/BAL, supporting liable diligent entree wherever permitted, moving the programme into randomized signifier 3 development, advancing regulatory plans successful the U.S. and Europe, and strengthening the company's equilibrium expanse and operating foundation.

BOT/BAL Remains Lead Development Focus

Armen described BOT/BAL arsenic a operation of an Fc-engineered CTLA-4 antibody and a PD-1 antibody, saying Agenus does not presumption the regimen arsenic "simply different CTLA-4 and PD-1 doublet." He said botensilimab was designed to assistance activate a broader immune response, including by priming T cells, reducing suppressive regulatory T cells, engaging myeloid cells and supporting immune memory.

→ What to Expect From Q2 Earnings arsenic Tech Strength Broadens

Read Entire Article